Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Amortization - Intangibles: 2018-2024

Historic Amortization - Intangibles for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Dec 2024 value amounting to $8.1 million.

  • Rocket Pharmaceuticals' Amortization - Intangibles fell 9.19% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 27.82%. This contributed to the annual value of $8.1 million for FY2024, which is 24.16% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Amortization - Intangibles stood at $8.1 million for FY2024, which was down 24.16% from $10.7 million recorded in FY2023.
  • Rocket Pharmaceuticals' Amortization - Intangibles' 5-year high stood at $10.7 million during FY2023, with a 5-year trough of -$2.9 million in FY2021.
  • Its 3-year average for Amortization - Intangibles is $6.2 million, with a median of $8.1 million in 2024.
  • Its Amortization - Intangibles has fluctuated over the past 5 years, first tumbled by 402.07% in 2021, then surged by 22,761.70% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Amortization - Intangibles (Yearly) stood at -$580,000 in 2020, then crashed by 402.07% to -$2.9 million in 2021, then skyrocketed by 98.39% to -$47,000 in 2022, then surged by 22,761.70% to $10.7 million in 2023, then decreased by 24.16% to $8.1 million in 2024.